Using unbiased protein interactomics screening and molecular validation, we found that TRIM56 directly interacted with FASN, a key lipogenesis factor driving hepatic steatosis in NAFLD/NASH. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.